Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bristol-Myers Squibb (BMY) Gets a Buy from Piper Sandler

Tipranks - Tipranks - Tue Apr 7, 6:10AM CDT

Piper Sandler analyst David Amsellem reiterated a Buy rating on Bristol-Myers Squibb today and set a price target of $75.00.

Easter Sale - 70% Off TipRanks

Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, Esperion, and Biogen. According to TipRanks, Amsellem has an average return of 6.5% and a 50.90% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol-Myers Squibb with a $62.94 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Bristol-Myers Squibb’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $12.5 billion and a net profit of $1.09 billion. In comparison, last year the company earned a revenue of $12.34 billion and had a net profit of $72 million

Read More on BMY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).